Trial Profile
A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter, International Study of Osimertinib as Maintenance Therapy in Patients With Locally Advanced, Unresectable EGFR Mutation-positive Non-Small Cell Lung Cancer (Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy (LAURA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Registrational; Therapeutic Use
- Acronyms LAURA
- Sponsors AstraZeneca; AstraZeneca AB
- 19 Feb 2024 According to an AstraZeneca media release, the data will be presented at a forthcoming medical meeting and shared with global regulatory authorities.
- 19 Feb 2024 Results presented in an AstraZeneca Media Release.
- 16 Oct 2023 Planned primary completion date changed from 1 Nov 2023 to 5 Jan 2024.